News
Impact of the combination of bevacizumab with erlotinib in patients with NSCLC and EGFR mutation on overall survival and time to disease progression
Dual inhibition of the epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) can delay resistance to chemotherapy in patients with advanced-stage non-small cell lung cancer (NSCLC). The study presented below examined the efficacy and safety of the erlotinib + bevacizumab combination compared to erlotinib monotherapy in these patients.
When the Cause of Hematomas in Anticoagulated Patients is Not Anticoagulants – Case Report
Not every bleeding during anticoagulation, especially if within the therapeutic range, can be…
Rebound effect after denosumab discontinuation in a patient with lung cancer
The case study of a patient with metastatic lung cancer describes the emergence of vertebral…
Prevention of Symptomatic Skeletal Events in Postmenopausal Women with Advanced ER-Positive Breast Cancer
Advanced breast cancer with the presence of estrogen receptors is one of the most common cancers…
Current Approaches to COPD Therapy According to GOLD Recommendations and in the Conditions of Czech Practice
Chronic Obstructive Pulmonary Disease (COPD) represents a significant global cause of morbidity and…
Impact of Rehabilitation on the Health of Patients with COPD
According to the Global Initiative for Chronic Obstructive Lung Disease (GOLD), pulmonary…
ESC 2022: Heart Failure with Preserved Ejection Fraction as an Underdiagnosed Problem: How to Increase Its Detection in Everyday Practice?
During this year's European Society of Cardiology Congress (ESC 2022), alarming information was…
Estimated Worldwide Prevalence of Population with AAT Deficiency with MZ Alleles
Alpha-1-antitrypsin deficiency (AATD) with the MZ genotype was until recently associated with…
Repeated Episodes of Respiratory Failure Due to Undiagnosed AAT Deficiency – Case Report
The case report from authors in Naples shows that alpha-1-antitrypsin deficiency (AATD) should be…
Persistent Symptom Control with s.c. Supplementation of C1 Inhibitor in Prophylactic Treatment of HAE
The open-label extension of the COMPACT study with subcutaneous C1 inhibitor in the prophylaxis of…
Conferences
News from the world of medicine
All conferences
Popular this week
- Multiple system atrophy
- Intermittent Fasting May Carry Significant Health Risks
- How Compassion Fatigue Threatens Doctors and Other Healthcare Workers
- Tuberous Sclerosis
- Modern approaches enhancing the efficiency of antibiotic therapy in hospital practice